Anaptysbio Stock Performance
| ANAB Stock | USD 17.42 0.62 3.44% |
The firm shows a Beta (market volatility) of 1.65, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, AnaptysBio will likely underperform. At this point, AnaptysBio has a negative expected return of -0.0145%. Please make sure to confirm AnaptysBio's mean deviation, jensen alpha, potential upside, as well as the relationship between the standard deviation and treynor ratio , to decide if AnaptysBio performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days AnaptysBio has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, AnaptysBio is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
Five Day Return 4.75 | Year To Date Return 30.39 | Ten Year Return 2.47 | All Time Return 2.47 |
1 | Anaptys Announces Participation in November and December Investor Conferences | 11/05/2024 |
2 | Acquisition by Eric Loumeau of 29150 shares of AnaptysBio subject to Rule 16b-3 | 11/08/2024 |
3 | Disposition of 2000 shares by Lizzul Paul F. of AnaptysBio at 40.0 subject to Rule 16b-3 | 11/22/2024 |
4 | Are Medical Stocks Lagging AnaptysBio This Year | 11/25/2024 |
5 | Disposition of 10000 shares by Renton Hollings of AnaptysBio at 25.0 subject to Rule 16b-3 | 11/29/2024 |
6 | Disposition of 2554 shares by Lizzul Paul F. of AnaptysBio at 21.81 subject to Rule 16b-3 | 12/03/2024 |
7 | Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary ... | 12/11/2024 |
8 | GSK Gets CHMP Nod for Expanded Use of HIV Combo Jemperli | 12/17/2024 |
9 | AnaptysBio Trading 9.1 percent Higher Time to Buy | 12/19/2024 |
10 | Acquisition by Ecor1 Capital, Llc of 65184 shares of AnaptysBio at 12.9182 subject to Rule 16b-3 | 12/30/2024 |
11 | Acquisition by Ecor1 Capital, Llc of 13268 shares of AnaptysBio at 12.9268 subject to Rule 16b-3 | 12/31/2024 |
12 | Acquisition by Ecor1 Capital, Llc of 6646 shares of AnaptysBio at 12.9506 subject to Rule 16b-3 | 01/02/2025 |
13 | Disposition of 34678 shares by Daniel Faga of AnaptysBio subject to Rule 16b-3 | 01/03/2025 |
14 | Disposition of 17850 shares by Daniel Faga of AnaptysBio subject to Rule 16b-3 | 01/06/2025 |
15 | Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference | 01/07/2025 |
16 | Disposition of 20645 shares by Schmid John P. of AnaptysBio at 8.54 subject to Rule 16b-3 | 01/13/2025 |
17 | Acquisition by Eric Loumeau of 7288 shares of AnaptysBio subject to Rule 16b-3 | 01/16/2025 |
18 | Acquisition by Schmid John P. of 16510 shares of AnaptysBio at 14.83 subject to Rule 16b-3 | 01/22/2025 |
19 | Disposition of 6387 shares by Daniel Faga of AnaptysBio at 15.3 subject to Rule 16b-3 | 01/24/2025 |
20 | AnaptysBio Trading Down 4.5 percent - Time to Sell - MarketBeat | 01/30/2025 |
| Begin Period Cash Flow | 71.3 M |
AnaptysBio |
AnaptysBio Relative Risk vs. Return Landscape
If you would invest 1,994 in AnaptysBio on November 2, 2024 and sell it today you would lose (252.00) from holding AnaptysBio or give up 12.64% of portfolio value over 90 days. AnaptysBio is currently does not generate positive expected returns and assumes 6.207% risk (volatility on return distribution) over the 90 days horizon. In different words, 55% of stocks are less volatile than AnaptysBio, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
AnaptysBio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for AnaptysBio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as AnaptysBio, and traders can use it to determine the average amount a AnaptysBio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0023
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ANAB |
Estimated Market Risk
| 6.21 actual daily | 55 55% of assets are less volatile |
Expected Return
| -0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average AnaptysBio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of AnaptysBio by adding AnaptysBio to a well-diversified portfolio.
AnaptysBio Fundamentals Growth
AnaptysBio Stock prices reflect investors' perceptions of the future prospects and financial health of AnaptysBio, and AnaptysBio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AnaptysBio Stock performance.
| Return On Equity | -1.62 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (2.90) % | ||||
| Operating Margin | (0.76) % | ||||
| Current Valuation | 116.44 M | ||||
| Shares Outstanding | 30.43 M | ||||
| Price To Earning | 81.21 X | ||||
| Price To Book | 6.28 X | ||||
| Price To Sales | 9.27 X | ||||
| Revenue | 17.16 M | ||||
| Gross Profit | (97.6 M) | ||||
| EBITDA | (143.16 M) | ||||
| Net Income | (163.62 M) | ||||
| Cash And Equivalents | 442.15 M | ||||
| Cash Per Share | 15.66 X | ||||
| Total Debt | 17.81 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 22.79 X | ||||
| Book Value Per Share | 2.77 X | ||||
| Cash Flow From Operations | (120.8 M) | ||||
| Earnings Per Share | (6.05) X | ||||
| Market Capitalization | 530.07 M | ||||
| Total Asset | 452.39 M | ||||
| Retained Earnings | (614.1 M) | ||||
| Working Capital | 369.39 M | ||||
| Current Asset | 297.84 M | ||||
| Current Liabilities | 16.6 M | ||||
About AnaptysBio Performance
By analyzing AnaptysBio's fundamental ratios, stakeholders can gain valuable insights into AnaptysBio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if AnaptysBio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if AnaptysBio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.33) | (0.34) | |
| Return On Capital Employed | (0.36) | (0.37) | |
| Return On Assets | (0.33) | (0.34) | |
| Return On Equity | (1.67) | (1.75) |
Things to note about AnaptysBio performance evaluation
Checking the ongoing alerts about AnaptysBio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AnaptysBio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| AnaptysBio generated a negative expected return over the last 90 days | |
| AnaptysBio has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 17.16 M. Net Loss for the year was (163.62 M) with loss before overhead, payroll, taxes, and interest of (97.6 M). | |
| AnaptysBio currently holds about 442.15 M in cash with (120.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 15.66. | |
| Over 98.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: AnaptysBio Trading Down 4.5 percent - Time to Sell - MarketBeat |
- Analyzing AnaptysBio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AnaptysBio's stock is overvalued or undervalued compared to its peers.
- Examining AnaptysBio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AnaptysBio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of AnaptysBio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AnaptysBio's stock. These opinions can provide insight into AnaptysBio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for AnaptysBio Stock analysis
When running AnaptysBio's price analysis, check to measure AnaptysBio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AnaptysBio is operating at the current time. Most of AnaptysBio's value examination focuses on studying past and present price action to predict the probability of AnaptysBio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AnaptysBio's price. Additionally, you may evaluate how the addition of AnaptysBio to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |